Takeda Pharmaceutical Company Limited (TAK) has received approval from the U.S. Food and Drug Administration (FDA) for ADZYNMA, a recombinant ADAMTS13 enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP). This is the first and only FDA-approved treatment for cTTP, an ultra-rare, chronic blood clotting disorder. The approval was supported by data from a Phase 3 trial and a continuation trial. This development does not affect Takeda's consolidated forecast for the fiscal year ending March 31, 2024.